AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04484870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral Danshu capsule
Description: Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
Study NCT01360320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract of Camellia Sinensis
Description: Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks~* 150mg EGCG two times daily (p.o.) over the course of three years.~* Colonoscopy after 3 years
Study NCT01360320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green tea extract of Camellia Sinensis followed by placebo
Description: Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks~* Placebo two times daily (p.o.) over the course of three years~* Colonoscopy after 3 years
Study NCT02426463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT02426463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Study NCT04380389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: hypoxia
Description: Brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.
Study NCT01290757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg Capsugel (T)
Study NCT01290757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg Qualicaps (R)
Study NCT01433016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C Sodium Octanoate
Description: 13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
Study NCT03487991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized sleep intervention
Description: Personalized feedback and recommendations based on study observations of sleep behavior and how participants cope with potentially sleep disruptive cognitions on their frequency and impact and on sleep efficiency. A written report is provided to participants and their initial modifications are monitored.
Study NCT03468244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized mRNA Tumor Vaccine
Description: subcutaneous injection with personalized mRNA tumor vaccine at least four times
Study NCT02719613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Study NCT02719613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
Study NCT02719613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Study NCT02719613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
Study NCT02719613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
Study NCT02719613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
Study NCT02719613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Study NCT00202761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIH
Description: Intensified training
Study NCT01544725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procedural sedation with ketamine-propofol combination
Description: K= Kétamine P= Propofol RSS= Ramsay Sedation Score~At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).~At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver).
Study NCT01544725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procedural sedation with ketamine alone
Description: K= Ketamine I= Intralipid placebo~At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).~At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver).
Study NCT00350571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief (behavioral therapy)
Description: up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
Study NCT00350571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drop out re-engagement motivational intervention
Description: Up to 3 phone or office based counseling sessions to promote reengagement in treatment
Study NCT00350571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care follow up
Description: routine counselor phone calls and letters
Study NCT03214861 — intervention group
Intervention type: OTHER
Intervention: Carbohydrate quality
Description: This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
Study NCT00687687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
Study NCT00687687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
Study NCT00687687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSI-201 (Iniparib)
Description: BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
Study NCT01203735 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valproic acid
Description: 800mg per day for entire period of RT
Study NCT01744249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
Study NCT01744249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
Study NCT01744249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sandostatin LAR
Description: Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
Study NCT01744249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
Study NCT02334982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-137
Description: TAK-137 tablets
Study NCT02334982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-137 placebo-matching tablets
Study NCT02814084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Internal Mammary Artery grafts
Description: Sternal Wound Edge Oxygenation in patients undergoing Coronary Artery bypass surgery with Bilateral Internal Mammary Artery grafts
Study NCT02814084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: The Prevena wound management system applies negative pressure to the closed wound for up to 7 days and is associated with lower rates of surgical site infection.
Study NCT04565093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iPACK
Description: Interspace between the popliteal artery and the capsule of the posterior knee (iPACK):~This is basically ultrasound guided peripheral nerve block performed by the anesthesiologists at the posterior side of the knee to control pain after TKA.
Study NCT04565093 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periarticular local infiltration analgesia (LIA)
Description: A mixture of Bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This intervention is commonly performed by the operating orthopedic surgeon to control pain after TKA.
Study NCT04341402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antifungal Nail Gel Study
Description: Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
Study NCT04242836 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MNREAD testing
Description: One randomly selected eye is included for each study participant. Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
Study NCT03712904 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo radiation
Study NCT03712904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study NCT00909337 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bosentan
Description: 2x62.5mg for 4 weeks, then 2x125mg
Study NCT02576639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520
Study NCT02576639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to CNP520 was supplied in capsules.
Study NCT02289677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATMOS Scope
Description: Video-laryngoscopy 1
Study NCT02289677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COOPDECH
Description: Video-laryngoscopy-1
Study NCT02289677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: Optical-laryngoscopy
Study NCT00564460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride 5 mg PO once daily for 8 weeks prior to TURP
Study NCT00564460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 8 weeks
Study NCT04585854 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Caffeine
Description: Consumption of 3 shots of espresso
Study NCT01877512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Change in daily dosage of Growth Hormone
Study NCT04236102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples
Description: Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.
Study NCT01730521 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise (Running)
Description: the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
Study NCT03679065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Study NCT03679065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
Study NCT03679065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Study NCT04504981 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Y2Prevent
Description: Y2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals
Study NCT02394535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT02394535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02394535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT02394535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02394535 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT01802008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-minute withdrawal time
Description: For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist.
Study NCT01802008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute withdrawal time
Description: For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist.
Study NCT01900795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V117957
Description: V117957 4.5 mg suspension taken orally after surgery.
Study NCT01900795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg tablets taken orally after surgery.
Study NCT01900795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally after surgery.
Study NCT02537249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
Study NCT02537249 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
Study NCT04838535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Raman spectrum
Description: The wavelength of the follicular fluids were scaned by Raman spectrum
Study NCT00940940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax (Live attenuated herpes zoster vaccine)
Description: 0.6 mL subcutaneous
Study NCT00940940 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: 0.65 mL subcutaneous
Study NCT01938326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Approach Method
Description: SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
Study NCT01943604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutella Breakfast
Description: Breakfast composed of bread and Nutella, milk and apple slices
Study NCT01683799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: 6-week behavioral treatment for insomnia
Study NCT01943604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waffle Breakfast
Description: Breakfast composed of waffles and syrup, milk, and apple slices
Study NCT02404142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curare (Atracurium)
Description: Curare (Atracurium) versus saline isotonic solution for tracheal intubation
Study NCT03854058 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic phrenic nerve stimulation
Description: cervical and cortical stimulation of N. Vagus
Study NCT02404142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline isotonic solution
Study NCT01634776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed oil
Description: Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
Study NCT01634776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Study NCT03488836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reciproc
Description: rotary reciprocating protocol
Study NCT03488836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: race rotary
Description: race rotary group protocol
Study NCT00722020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEST
Description: 15 minutes of HFCWO via the Vest 2-3 times daily
Study NCT00764218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive airway pressure treatment
Description: Positive airway pressure treatment as long as necessary
Study NCT00764218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No positive airway pressure treatment
Description: No treatment
Study NCT00477685 — intervention group
Intervention type: DEVICE
Intervention: OculusGen Biodegradable Collagen Matrix Implant
Description: OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
Study NCT01883167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Description: RDEA3170 10 mg once daily (qd)
Study NCT01883167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Description: Febuxostat 40 mg qd
Study NCT01883167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo qd
Study NCT03451045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg
Description: Subjects will receive lenabasum 20 mg twice daily.
Study NCT03451045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 5 mg
Description: Subjects will receive lenabasum 5 mg twice daily.
Study NCT03451045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo twice daily.